The differences in the inhibitory effects of anti-Ad5 antibodies on the antitumor effects of OAd5 among the studies were due to the differences in the experimental conditions, including the virus doses, anti-Ad5 antibody titers, administration routes of OAd5, and cancer cell types. This evidence concerns the gene PSEN2 and cancer.